BETA

Activities of Esko SEPPÄNEN related to 2008/0211(COD)

Plenary speeches (1)

Protection of animals used for scientific purposes (debate)
2016/11/22
Dossiers: 2008/0211(COD)

Amendments (27)

Amendment 12 #
Proposal for a directive
Recital 7
(7) This Directive should also cover embryonic and foetal forms of vertebrate animals, as there is scientific evidence showing that such forms in the last third of their development have an increased risk of experiencing pain, suffering and distress, which may also affect negatively their subsequent development. Scientific evidence has also shown that procedures on embryonic and foetal forms at an earlier stage of development could result in pain, suffering, distress or lasting harm, should the developmental forms be allowed to live beyond the first two thirds of their development.deleted
2009/02/23
Committee: ITRE
Amendment 17 #
Proposal for a directive
Recital 10
(10) Animals have an intrinsic value in themselves which must be respected. There are also ethical concerns of the general public as regards the use of animals in procedures. Therefore, the animals should always be treated as sentient creatures and their use in scientific procedures should be restricted to areas which advance science andfundamental knowledge in science, since this may ultimately have benefits, for example, to human or animal health, or the environment. Use of animals for scientific procedures in other areas under Community competence should be prohibited.
2009/02/23
Committee: ITRE
Amendment 20 #
Proposal for a directive
Recital 16
(16) With current scientific knowledge the use of non-human primates in scientific procedures is still necessary in biomedical research. Due to their genetic proximity to human beings and to their highly developed social skills, the use of non- human primates in scientific procedures raises specific ethical and practical problems in terms of meeting their behavioural, environmental and social needs in a laboratory environment. Furthermore, the use of non-human primates is of the highest concern to the public. Therefore the use of non-human primates should only be allowed in those essential biomedical areas for the benefit of human beings for which no other replacement alternative methods are yet available and only in cases where the procedures are carried out in relation to clinical conditions having a substantial impact on patients’ day-today functioning as being either life-threatening or debilitating, or for the preservation of the respective non-human primate species. Fundamental research in some areas of the biomedical sciences can provide important new information relevant to many life- threatening and debilitating human conditions. The reference toat some future stage to many life- threatening orand debilitating clinical conditions is established terminology in EC legislation as reflected in Regulation 141/2000/EC, in Directive 2001/20/EC, Regulation 726/2004/EC and Commission Regulation 507/2006/EChuman conditions.
2009/02/23
Committee: ITRE
Amendment 24 #
Proposal for a directive
Recital 18
(18) TIn order to gradually end the captureing of anon-human primatels from the wild is highly stressful for the animals and increases the risk of injury and suffering during capture and transport. In order to gradually end the capturing of animals from the wild for breeding purposes, only animals that are the offspring of an animal which has been bred in captivity should be made available for use in scientific procedures as soon as possiblefor breeding purposes, a thorough scientific evaluation should be conducted as soon as possible on the feasibility of restricting the use of animals that are the offspring of an animal which has been bred in captivity. Establishments breeding and supplying non-human primates should therefore have a strategy in place to support and facilitate the progressive move towards that goal.
2009/02/23
Committee: ITRE
Amendment 34 #
Proposal for a directive
Recital 45
(45) The European Centre for the Validation of Alternative Methods is established within the Joint Research Centre of the Commission and coordinates the validation of alternative approaches in the Community. However, there is an increasing need for new methods to be developed and proposed for validation. To provide the necessary mechanisms at Member State level, a reference laboratory for the validation of alternative methods should be designated by each Member State. Member States should designate reference laboratories which are accredited in accordance with Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances in order to ensure coherent and comparable quality of the results. In addition, the remit of the European Centre for the Validation of Alternative Methods should be extended to include the coordination and promotion of the development and use of alternatives to animal experiments.
2009/02/23
Committee: ITRE
Amendment 42 #
Proposal for a directive
Article 2 – paragraph 2 – point b a (new)
(ba) animals covered by point (a) or (b) which have been genetically manipulated, cloned or are the offspring of, the subsequent generation of or are from the line of an animal covered by point (a) or (b) which has been genetically manipulated or cloned.
2009/02/23
Committee: ITRE
Amendment 43 #
Proposal for a directive
Article 2 – paragraph 3
3. This Directive shall apply to animals used in procedures, which are at an earlier stage of development than that referred to in point (a) of paragraph 2, if the animal is to be allowed to live beyond that stage of development and is likely to experience pain, suffering, distress or lasting harm after it has reached that stage of development.deleted
2009/02/23
Committee: ITRE
Amendment 45 #
Proposal for a directive
Article 3 – paragraph 6 a (new)
6a. 'competent authority' means the authority or authorities designated by each Member State as being responsible for supervising the enforcement of this Directive.
2009/02/23
Committee: ITRE
Amendment 57 #
Proposal for a directive
Article 6 – paragraph 2
2. Competent authorities may grant exemptions from paragraph 1 on the basis of scientific justification that the purpose of the procedure cannot be achieved by the use of a humane method of killing. Notwithstanding any exemption, animals shall be killed with a minimum of pain, suffering and distress.
2009/02/23
Committee: ITRE
Amendment 61 #
Proposal for a directive
Article 6 a (new)
Article 6a Adoption of stricter measures This Directive shall not prevent Member States from applying or adopting stricter national measures aimed at improving the welfare and protection of animals used in experiments.
2009/02/23
Committee: ITRE
Amendment 82 #
Proposal for a directive
Article 9 – paragraph 2
2. Competent authorities may grant exemptions from paragraph 1 on the basis of scientificcompelling scientific and societal justification that the purpose of the procedure cannot be achieved by the use of an animal which has been bred for use in procedures.
2009/02/23
Committee: ITRE
Amendment 87 #
Proposal for a directive
Article 10 – paragraph 2 a (new)
2a. For the purpose of paragraph 1, the Commission shall, within five years after the entry into force of this Directive, carry out an animal welfare assessment and a feasibility evaluation of the implementation of the requirements set out in paragraph 1.
2009/02/23
Committee: ITRE
Amendment 95 #
Proposal for a directive
Article 15 – paragraph 1
1. Member States shall ensure that all procedures are classified as 'up to mild', 'moderate', 'severe' or 'non-recovery' on the basis of the duration and intensity of potential pain, suffering, distress and lasting harm, the frequency of intervention, the deprivation of ethological needs and the use of anaesthesia or analgesia or both or 'severe' in accordance with Annex VIIa.
2009/02/23
Committee: ITRE
Amendment 108 #
Proposal for a directive
Article 16 – paragraph 2
2. By way of derogation from paragraph 1, the competent authority, on the basis of scientific justification, may allow re-use of an animal as long as the animal is not used more than once after having undergone a procedure entailing severe pain, distress or equivalent sufferingwhere the previous procedure performed on the animal is classified as ‘moderate’ or 'up to mild' and the further procedure is classified as 'moderate', 'up to mild' or as 'non-recovery'.
2009/02/23
Committee: ITRE
Amendment 118 #
Proposal for a directive
Article 22 – paragraph 1
1. Where an establishment no longer complies with requirements set out in this Directive, the competent authority shall suspend or withdraw its authorisation. Member States shall establish an appropriate mechanism for appeals against suspension or withdrawal of authorisation.
2009/02/23
Committee: ITRE
Amendment 121 #
Proposal for a directive
Article 23 – paragraph 2
2. The design, construction and method of functioning of the installations and equipment referred to in paragraph 1 shall ensure that the procedures are carried out as effectively as possible, obtaining consistent results with the minimum number of animals and the minimum degree of pain, suffering, distress or lasting harm.
2009/02/23
Committee: ITRE
Amendment 122 #
Proposal for a directive
Article 25 – paragraph 2
2. The permanent ethical review body shall include as a minimum the designated veterinarian, the person(s) responsible for the welfare and care of the animals in the establishment and, in the case of a user establishment, as the scientific member a person with expertise in the "3Rs" (Replacement, Reduction, Refinement), and an independent lay person.
2009/02/23
Committee: ITRE
Amendment 129 #
Proposal for a directive
Article 26 – paragraph 1 – point d – introductory part
(d) review annually all projects classified as "severe" or on non-human primates and every three years the other projects which are of more than 12 months duration, focusing in particular on:
2009/02/23
Committee: ITRE
Amendment 130 #
Proposal for a directive
Article 26 – paragraph 2 – subparagraph 2
The records shall be submittedmade available to the competent authority upon request. Member States shall pay particular attention to the collection, collation and publication of records relating to projects classified as severe or on non-human primates in order to provide information which can improve animal welfare and further the 3Rs.
2009/02/23
Committee: ITRE
Amendment 137 #
Proposal for a directive
Article 29 – paragraph 1 – introductory part
1. Member States shall wherever possible ensure that all breeding, supplying and user establishments keep records of the following:
2009/02/23
Committee: ITRE
Amendment 138 #
Proposal for a directive
Article 29 – paragraph 1 – point a
(a) the number and the species of vertebrate animals bred, acquired, supplied, released or re- homed;
2009/02/23
Committee: ITRE
Amendment 146 #
Proposal for a directive
Article 34 – paragraph 1
1. The Commission may undertake controls of the infrastructure and operation of national inspections in Member States to ensure that severity classifications are applied correctly and uniformly in the EU territory.
2009/02/23
Committee: ITRE
Amendment 158 #
Proposal for a directive
Article 36 – paragraph 1 – introductory part
1. TWhen required, the user establishment or the person scientifically responsible for the project shall submit an application for the project authorisation, which shall include the following:
2009/02/23
Committee: ITRE
Amendment 171 #
Proposal for a directive
Article 37 – paragraph 4
4. Ethical evaluation shall be performed in a transparent manner, by integrating the opinion of independent parties. For intellectual property and security reasons, confidentiality should be ensured.
2009/02/23
Committee: ITRE
Amendment 186 #
Proposal for a directive
Article 42 – paragraph 2
2. Any amendment or renewal of a project authorisation that involves severe procedures or non- human primates, or a moderate or greater increase in animal harm shall be subject to a further favourable ethical evaluation and authorisation by the competent authority.
2009/02/23
Committee: ITRE
Amendment 187 #
Proposal for a directive
Article 42 – paragraph 3
3. The competent authority may withdraw the project authorisation where the project is not carried out in accordance with the project authorisation and may cause a deterioration in animal welfare.
2009/02/23
Committee: ITRE
Amendment 222 #
Proposal for a directive
Annex VII a (new)
ANNEX VIIa General Definitions of Degrees of Severity referred to in Article 15(1) In general: Unless the contrary is known or established it should be assumed that procedures that cause pain in humans also cause pain in animals. No pain or mild stress/pain: Severity Grade 1 Interventions and manipulations in animals for experimental purposes as a result of which the animals experience no pain or mild pain, suffering and injury, or no anxiety or mild anxiety and no significant impairment of their general condition. Examples: - studies with differing feed compositions or with unphysiological diet, without manifest clinical signs or symptoms; - withdrawal of blood samples; injection (s.c., i.m., i.p., i.v.) of a drug; - one single retrobulbar blood sample or several retrobulbar blood samples at intervals of > 14 days (alternating punctures), under brief anaesthesia; - subcutaneously channelled venous catheters; - NMR measurements (nuclear spin resonance), with or without sedation of the animals; - test of contrast media by means of exploratory echography; - application of substances with known innocuous effects (vehicle-control); - tolerability studies which give rise to transient, mild, local or systemic reactions and, owing to the mode of administration or sample collection, impose no significant stress on the animals; - bronchoscopy, broncho-alveolar lavage or pulmonary-function test in anaesthetized animals; - models with ECG recordings in the conscious dog; - open-field test, labyrinth tests, the staircase test; - circadian-rhythm model. Moderate Stress: Severity Grade 2 Interventions and manipulations in animals for experimental purposes which subject the animals to a brief episode of moderate stress, or a moderately long to long-lasting episode of mild stress (pain, suffering, or injury, extreme anxiety, or significant impairment of general condition). Examples: - models with telemetric heart-rate measurements in the conscious animal by means of catheters/transmitters implanted in the abdominal cavity; - surgical treatment or castration of female animals under anaesthesia; - studies with unphysiological diet, with manifest clinical signs or symptoms; - implantation of gene-technologically altered embryos in foster-mother mice; - spontaneous diabetes mellitus; - genetically engineered mouse strains with oncogenes, if the experiment is prematurely terminated according to defined criteria (that is, if the study is finished before the tumour exceeds a pre- defined size); - obese mouse with diabetes mellitus; - repetitive daily withdrawal of blood samples from the tail vein of the rat over five days; - repeated retrobulbar blood samples under brief anaesthesia (at the most three times within 14 days, alternating, and on the last occasion preterminally); - surgical interventions: - implantation of catheters in the abdominal aorta or bile duct, - implantation of minipumps intravenously, - acute toxicity tests, acute tolerability studies; range-finding studies, chronic toxicity/carcinogenicity tests; toxicokinetic tests, - petit-mal model (i.e. for epilepsy studies), - collection of cerebrospinal fluid via cannula (microdialysis) in the rat. Severe stress: Severity Grade 3 Interventions and manipulations in animals for experimental purposes which cause the animals severe to very severe stress, or subject them to a moderately long to long-lasting episode of moderate stress (severe pain, prolonged suffering or severe injury; extreme and persistent anxiety, or significant and persistent impairment of general condition). Examples: - bacteria: models with infections for screening new antibiotics; - transmitted rheumatoid arthritis; - auto-immunely induced arthritis; - genetically engineered mouse strains with oncogenes, without premature termination of the experiment; - joint transplantations; - transplantation of a functional internal organ (i.e. kidney, pancreas transplantation); - models with induction of clinically manifest cardiac insufficience; - lethal infectious and neoplastic disease without premature euthanasia; - knock-out mice with massive deficiency symptoms.
2009/02/23
Committee: ITRE